Why the study?
HCM presents with heterogeneous clinical profiles and independent complication pathways that require characterization regarding their prognostic implications.
This review highlights the heterogeneity of hypertrophic cardiomyopathy and emphasizes the importance of recognizing distinct clinical profiles to understand patient prognosis.
No takes yet. Share an insight, caveat, or question.
Supports recognizing distinct HCM subgroups for prognosis; leaves open prospective validation before guiding management.
Russo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: